Abstract
The recent demonstration of human glandular kallikrein (hK2) expression in a breast carcinoma cell line has suggested that this putatively prostate-restricted, steroid hormone-regulated protease may also be expressed in breast epithelium in vivo and secreted into the mammary duct system. Given that the only substrate yet identified for hK2 activity is the precursor of prostate-specific antigen (PSA), the expression of which in breast carcinomas may be associated with favourable prognosis, our purpose was to examine the expression pattern of both hK2 and PSA in breast tumour tissues. Cytosolic extracts of 336 primary breast carcinomas prepared for routine oestrogen receptor (ER) and progesterone receptor (PR) analysis, as well as 31 nipple aspirates from six women with non-diseased mammary glands, were assayed for hK2 and PSA using immunofluorometric assays developed by the authors. In the tumour extracts, measurable hK2 and PSA concentrations were detected in 53% and 73% of cases respectively, and were positively correlated to each other (r = 0.59, P = 0.0001). Higher concentrations of PSA and hK2 were found in tumours expressing steroid hormone receptors (P = 0.0001 for PSA and P = 0.0001 for hK2, by Wilcoxon tests for both ER and PR), and both PSA (r = 0.25, P = 0.0001) and hK2 (r = 0.22, P = 0.0001) correlated directly with PR levels. A negative correlation between patient age and PSA (r = –0.12, P = 0.03) was also found. Both proteins were present in nipple aspirate fluid at relatively high concentrations which were positively correlated (r = 0.53, P = 0.002). The molecular weights of the immunoreactive species quantified by the hK2 and PSA assays were established by high-performance liquid chromatography (HPLC) and were consistent with the known molecular weights of hK2 and PSA. Together these data provide the first evidence, to our knowledge, that both malignant breast tissue and normal breast secretion contain measurable quantities of hK2, and that the degree of hK2 expression or secretion is directly proportional to the expression of PSA and steroid hormone receptors. hK2 expression may therefore be a marker of steroid hormone action in breast tissue. © 2000 Cancer Research Campaign
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Black MH, Maglara A, Obiezu C, Melegos DN, Wolfert RL and Diamandis EP (1999) Development of an ultrasensitive immunoassay for human glandular kallikrein (hK2) with no cross reactivity from prostate specific antigen (PSA). Clin Chem 45: 790–799
Clements JA, Mukhtar A, Verity K, Pullar M, McNeill P, Cummins J and Fuller PJ (1996) Kallikrein gene expression in human pituitary tissues. Clin Endocrinol 44: 223–231
Cohen P, Graves HCB, Peehl DM, Kamarei M, Giudice LC and Rosenfeld RG (1992) Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046–1053
Corey E, Buhler KR and Vessella RL (1997) Cross-reactivity of ten anti-prostate-specific antigen monoclonal antibodies with human glandular kallikrein. Urology 50: 567–572
Cramer SD, Chen Z and Peehl DM (1996) Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. J Urol 156: 526–531
Diamandis EP (1996) BRCA1 protein products: antibody specificity, functional motifs and secreted tumour suppressions. Nat Genet 13: 268
Diamandis EP and Yu H (1995) New biological functions of prostate specific antigen?. J Clin Endocrinol Metab 80: 1515–1517
Diamandis EP and Yu H (1997) Nonprostatic sources of prostate-specific antigen. Urol Clin – Am 24: 275–282
Diamandis EP, Yu H and Sutherland DJA (1994) Detection of prostate specific antigen immunoreactivity in breast tumors. Breast Cancer Res Treat 32: 301–310
Ferguson RA, Yu H, Kalyvas M, Zammit S and Diamandis EP (1996) Ultrasensitive detection of prostate specific antigen by a time-resolved immunofluorometric assay and the Immulite® Immunochemiluminescent third generation assay: potential applications in prostate and breast cancers. Clin Chem 42: 675–684
Fichtner J, Graves HCB, Thatcher K, Yemoto C and Shortliffe M (1996) Prostate specific antigen releases a kinin-like substance on proteolysis of seminal vesicle fluid that stimulates smooth muscle contraction. J Urol 155: 738–742
Finlay JA, Evans CL, Day JR, Payne JK, Mikolajczyk SD, Millar LS, Kuus-Reichel K, Wolfert RL and Rittenhouse HG (1998) Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 51: 804–809
Foretova L, Garber JE, Sadowsky NL, Verselis SJ and Li FP (1996) Prostate-specific antigen in nipple aspirate. Lancet 347: 1631
Hsieh M, Charlesworth MC, Goodmanson M, Zhang S, Seay T, Klee GG, Tindall DJ and Young CYF (1997) Expression of human prostate-specific glandular kallikrein protein (hK2) in the breast cancer cell line T47-D. Cancer Res 57: 2651–2656
Killian CS, Corral DA, Kawinski E and Constantine RI (1993) Mitogenic response of osteoblast cells to prostate specific antigen suggests an activation of latent TGF-β and a proteolytic modulation of cell adhesion receptors. Biochem Biophys Res Commun 192: 940–947
Kumar A, Mikolajczyk SD, Goel AS, Millar LS and Saedi MS (1997) Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein. Cancer Res 57: 3111–3114
Lai LC, Erbas H, Lennard TW and Peaston RT (1996) Prostate-specific antigen in breast cyst fluid: possible role of prostate-specific antigen in hormone-dependent breast cancer. Int J Cancer 66: 743–746
Lopez-Otin C and Diamandis EP (1998) Breast and prostate cancer: common epidemiologic, genetic and biochemical features. Endocr Rev 19: 365–396
Lovgren J, Piironen T, Overmo C, Dowell B, Karp M, Pettersson K, Lilja H and Lundwall A (1995) Production of recombinant PSA and hK2 and analysis of their immunologic cross-reactivity. Biochem Biophys Res Commun 213: 888–895
Lovgren J, Rajakoski K, Karp M, Lundwall A and Lilja H (1997) Activation of the zymogen form of prostate-specific antigen by human kallikrein 2. Biochem Biophys Res Commun 238: 549–555
McCormack RT, Rittenhouse HG, Finlay JA, Sokoloff RL, Wang TJ, Wolfert RL, Lilja H and Oesterling JE (1995) Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology 45: 729–744
McGuire WL, Horwitz KB, Pearson OH and Segaloff A (1977) Current status of estrogen and progesterone receptors in breast cancer. Cancer 39: 2934–2947
Piironen T, Lovgren J, Karp M, Eerola R, Lundwall A, Dowell B, Lovgren T, Lilja H and Pettersson K (1996) Immunofluorometric assay for sensitive and specific measurement of human prostate glandular kallikrein (hK2) in serum. Clin Chem 42: 1034–1041
Riegman PH, Vlietstra RJ, Suurmeijer L, Cleutjens CB and Trapman J (1992) Characterization of the human kallikrein locus. Genomics 14: 6–11
Saedi MS, Cass MMJ, Goel AS, Grauer L, Hogen KL, Okaneya T, Griffin BY, Klee GG, Young CY-F and Tindall DJ (1995) Overexpression of a human prostate-specific glandular kallikrein, hK2, in E. coli and generation of antibodies. Mol Cell Endocrinol 109: 237–241
Sauter ER, Daly M, Linehan K, Ehya H, Engstrom PF, Bonney G, Ross EA, Yu H and Diamandis EP (1996) Prostate specific antigen levels in nipple aspirate fluid correlate with breast cancer risk. Cancer Epidemiol Biomarkers Prev 5: 967–970
Takayama TK, Fujikawa K and Davie EW (1997) Characterization of the precursor of prostate-specific antigen. J Biol Chem 272: 21582–21588
Yu H, Diamandis EP, Levesque M, Giai M, Roagna R, Ponzone R, Sismondi P, Monne M and Croce C (1996) Prostate specific antigen in breast cancer, benign breast disease and normal breast tissue. Breast Cancer Res Treat 40: 171–178
Yu H, Diamandis EP, Monne M and Croce CM (1995) Oral contraceptive-induced expression of prostate specific antigen in the female breast. J Biol Chem 270: 6615–6618
Yu H, Diamandis EP and Sutherland DJA (1994) Immunoreactive prostate specific antigen levels in female and male breast tumours and its association with steroid hormone receptors and patient age. Clin Biochem 27: 75–79
Yu H, Giai M, Diamandis EP, Katsaros D, Sutherland DJA, Levesque MA, Roagna R, Ponzone R and Sismondi P (1995) Prostate specific antigen is a new favorable prognostic indicator for women with breast cancer. Cancer Res 55: 2104–2110
Yu H, Levesque MA, Clark GM and Diamandis EP (1998) Prognostic value of prostate-specific antigen for women with breast cancer: a large U.S. cohort study. Clin Cancer Res 4: 1489–1497
Zarghami N, Grass L and Diamandis EP (1997) Steroid hormone regulation of prostate specific antigen gene expression in breast cancer. Br J Cancer 75: 579–588
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Black, M., Magklara, A., Obiezu, C. et al. Expression of a prostate-associated protein, human glandular kallikrein (hK2), in breast tumours and in normal breast secretions. Br J Cancer 82, 361–367 (2000). https://doi.org/10.1054/bjoc.1999.0927
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.1999.0927
Keywords
This article is cited by
-
Prostata: Anatomie und Physiologie
Journal für Urologie und Urogynäkologie/Österreich (2020)
-
Prostata: Anatomie und Physiologie
Urologie in der Praxis (2019)
-
Sensitive protein detection via triple-binder proximity ligation assays
Nature Methods (2007)
-
Human kallikrein 2 (hK2) mRNA in peripheral blood of patients with thyroid cancer
Journal of Cancer Research and Clinical Oncology (2003)